545
Participants
Start Date
August 15, 2024
Primary Completion Date
October 30, 2025
Study Completion Date
May 31, 2026
0.75% phentolamine ophthalmic solution
Once daily dosing
Placebo
Once daily dosing
United States, Rochester
United States, Garner
United States, Longwood
United States, Delray Beach
United States, Goodlettsville
United States, Memphis
United States, Athens
United States, San Antonio
United States, Phoenix
United States, Scottsdale
United States, Glendale
United States, Newport Beach
United States, Warwick
Lead Sponsor
Ocuphire Pharma, Inc.
INDUSTRY